There is currently no FDA approved pharmaceuticals on the market for prevention and reduction of hypertrophic scarring. In addition to small molecule and monoclonal antibody drug candidates, there are numerous companies  investigating or planning to investigate a variety of proposed anti-scarring therapies in clinical trials. The companies include large and small pharmaceutical, chemical and biotechnology companies, as well as universities, government agencies and other private and public research organizations.